Research

The benefits of biosimilar trials in the NHS

A new campaign led by NIHR CRN's Business Development and Marketing team, "Focus on biosimilars", explores some of the key questions associated with unlocking the potential benefits of biosimilars in the NHS through clinical trials. Biologic drugs have revolutionised the treatment of many serious and chronic illnesses in the NHS including rheumatoid arthritis and Inflammatory Bowel Disease (IBD), but are expensive to develop. They are thus expensive for the NHS to purchase resulting in restricted access for patients. As the patent protection for a number of leading biologic drugs is about to expire, the race is on to develop less expensive similar versions of biologics known as biosimilars.

Biosimilars have the promise of a smaller price tag and may well hold the key to ensuring the sustainability of our globally renowned public healthcare system. They will further broaden access to cutting edge treatments by providing new treatment options for patients just below the current biologics prescribing threshold. The acceptance of biosimilars across the NHS in recent years has rapidly accelerated with the clinical evidence base of biosimilars growing and the realisation of their benefits and cost savings.

"Focus on biosimilars" explores some of the key questions associated with unlocking the potential benefits of biosimilars in the NHS. To explore the campaign visit the NIHR website.